Scholarlink

Background <p>It is controversial whether or not total thyroidectomy followed by radioactive iodine ablation (RAI-a) (30&#xa0;mCi = 1.1&#xa0;GBq) is mandatory in intermediate-risk patients with lateral neck lymph node metastasis (cN1b).</p> Methods <p>This retrospective observational study enrolled PTC patients classified preoperatively as the intermediate-risk with cN1b from January 2010 to December 2017 according to the guidelines for thyroid tumors of the Japanese Association of Endocrine Surgeons (JAES) since 2009. We analyzed recurrence-free survival (RFS) rates estimated by the Kaplan–Meier method in the patients classified into three groups: 1) total thyroidectomy (TTx) followed by lateral neck lymph node dissection (LLND) with RAI-a, 2) TTx + LLND without RAI-a, 3) hemithyroidectomy + LLND. In addition, propensity score analysis adjusted by&#xa0;clinical parameters was performed.</p> Results <p>Two hundred eighty-eight patients with intermediate-risk PTC were identified. Among them, 87 patients with cN1b were analyzed.</p> <p>Five-year RFS rates in 1), 2), and 3) groups were 85.0%, 100%, and 90.9%, respectively. The analysis of 1) and 2) groups by propensity score matching revealed 5-yr RFS rates of 84.1% and 100%, respectively (<i>p</i> &lt; 0.0432).</p> Conclusions <p>There was no evidence to support the use of 30&#xa0;mCi (1.1GBq) radioactive iodine postoperatively to prevent recurrence in intermediate-risk PTC patients with cN1b.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of extent thyroidectomy and radioactive iodine ablation for disease free survival in the intermediate-risk patients with lateral neck lymph node metastasis: a retrospective and tentative real-world approach

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月3日

查看全文
  • Kiyomi Horiuchi,
  • Yuki Yamanashi,
  • Tomoyoshi Nakai,
  • Juro Yanagida,
  • Yusaku Yoshida,
  • Yoko Omi,
  • Takahiro Okamoto

摘要

Background

It is controversial whether or not total thyroidectomy followed by radioactive iodine ablation (RAI-a) (30 mCi = 1.1 GBq) is mandatory in intermediate-risk patients with lateral neck lymph node metastasis (cN1b).

Methods

This retrospective observational study enrolled PTC patients classified preoperatively as the intermediate-risk with cN1b from January 2010 to December 2017 according to the guidelines for thyroid tumors of the Japanese Association of Endocrine Surgeons (JAES) since 2009. We analyzed recurrence-free survival (RFS) rates estimated by the Kaplan–Meier method in the patients classified into three groups: 1) total thyroidectomy (TTx) followed by lateral neck lymph node dissection (LLND) with RAI-a, 2) TTx + LLND without RAI-a, 3) hemithyroidectomy + LLND. In addition, propensity score analysis adjusted by clinical parameters was performed.

Results

Two hundred eighty-eight patients with intermediate-risk PTC were identified. Among them, 87 patients with cN1b were analyzed.

Five-year RFS rates in 1), 2), and 3) groups were 85.0%, 100%, and 90.9%, respectively. The analysis of 1) and 2) groups by propensity score matching revealed 5-yr RFS rates of 84.1% and 100%, respectively (p < 0.0432).

Conclusions

There was no evidence to support the use of 30 mCi (1.1GBq) radioactive iodine postoperatively to prevent recurrence in intermediate-risk PTC patients with cN1b.